drugset / Trial / NCT04584307
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to examine the role of an immune modulatory drug (IMID) in combination with elotuzumab, in a lenalidomide-free approach to maintenance therapy following second unplanned autologous peripheral blood stem cell transplant (PBSCT) for relapsed multiple myeloma.
Timeline
- Start
- 2021-04
- Primary completion
- 2023-12
- Completion
- 2024-12
Outcome
Outcome not reported
Stopped (Business): “Funder pulled support/funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elotuzumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Elotuzumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |